Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
posted on
Dec 02, 2019 12:39PM
Back in 2018, BAN2401/Aducanumab Phase 2 results were announced by Biogen and Eisai. Here's a couple company news releases. Dig further though and you will find criticism of how they mined the data. Somewhat similar criticism to the Phase 3 results that they'll present this week.